South African President Cyril Ramaphosa, who is also the ACT-Accelerator co-chair.

The G20 Global Health Summit on Friday elicited more promises from wealthy nations to share COVID-19 vaccines, an undertaking by drug companies to make over a billion doses available by year-end – and an indication by the European Union that it would propose an alternative to the TRIPS waiver at the next World Trade Organization (WTO) meeting.

Hosted by Italy and the European Commission (EC), the summit ended with the adoption of the Rome Declaration, a 16-point commitment to improving pandemic preparedness, increasing local manufacturing capacity and investing in worldwide health systems.

Team Europe – primarily France, Italy and Germany – promised to share 100 million vaccine doses with low- and middle-income countries (LMIC) by the end of the year, while Pfizer committed to manufacturing a billion vaccine doses, Johnson & Johnson 200 million and Moderna 100 million – some of which would be supplied “at cost” to poor countries.

However, the European Union stood firmly against the proposal for a waiver on intellectual property rights on COVID-19 products under the Trade-Related Intellectual Property Rights (TRIPS) agreement during the pandemic – the TRIPS waiver proposal made by India and South Africa to the WTO.

“I’ve been listening very carefully to the developing countries…and they are complaining that it is difficult for them to use the flexibilities of TRIPS within the Doha Declaration,” EC President Ursula von der Leyen told a media briefing after the summit.

The European Union (EU) had thus decided to provide developing countries with “certainty” that they could use the flexibilities contained in the Doha Declaration during the pandemic, added Von der Leyen.

EU to Propose Third Way at WTO Meeting in June

EC President Ursula von der Leyen

The EU intends to propose a “third way” to the WTO meeting in June, based on “trade facilitation and disciplines on export restrictions, support for the expansion of production, and clarifying and simplifying the use of compulsory licences during crisis times”, she added.

“It’s important that the G20 has convened behind the Doha Declaration and the TRIPS agreement, and will work within it, with flexibilities,” she added.

The EU’s entrenched position comes despite growing support for the TRIPS waiver – including an indication by the US that it was willing to move to text-based negotiations on the proposal put forward by South Africa and India.

In addition, on Friday  62 WO members submitted a revised proposal on the WTO IP waiver “from certain provisions of the TRIPS Agreement for the Prevention, Containment and Treatment of COVID-19”, as reported by KEI International. 

The revised proposal narrows the scope of the waiver to COVID-19 “health products and technologies” and also calls for it to remain in force “for at least three years from the date of this decision” to be reviewed by the WTO General Council after that.

Despite the EU decision, WTO Director-General Ngozi Okonjo-Iweala told the summit that WTO member states should get ready for text-based negotiations on the proposed waiver. 

“We must act now to get all our ambassadors to the table to negotiate a text. This is the only way we can move forward quickly, we can’t move forward with speeches and polemics,” she told the summit.

“I am hopeful that by July we can make progress on a text and by our 12th Ministerial Conference in December, WTO members can agree on a pragmatic framework that offers developing countries near automaticity in access to health technologies, whilst also preserving incentives for research and innovation,” she added.

However, South African President Cyril Ramaphosa, who is also the co-chair of the Access to COVID-19 (ACT) Accelerator – the WHO-led global effort against COVID-19, said that “it cannot be justified that in this 21st century, Africa has only received 20 million vaccine doses, which is apparently 2% of the global supply”.

Describing the fight against the pandemic as a “war”, Ramaphosa said all countries needed weapons to fight the virus which was why his country and India had proposed a temporary TRIPS waiver.

“Such a waiver would enable developing countries, in particular, to expand their pharmaceutical sectors to facilitate technology and skills transfer, and above all, at this point in time, save lives,” said Ramaphosa.

IMF Boosts Global Reserves to Finance ‘Exit from COVID-19 Crisis’

IMF Director-General Kristalina Georgieva

IMF Director-General Kristalina Georgieva warned the summit of the “dangerous divergence of economic fortunes”, as the gap widens between wealthy countries that have access to vaccines in poor countries that do not.

The IMF estimated that $50 billion was needed to address three key issues – vaccinating 60% of the world’s population by 2022; protection against variants, including possible booster shots; and public health measures to manage the pandemic while vaccinations were taking place.

With the support of our membership, we are working towards making an important contribution to the exit from this crisis by boosting global reserves with $650 billion special drawing rights — particularly important for countries faced with the toughest challenges.  We are stepping up lending where needed, and we are working on debt sustainability,” said Georgieva.

“Pledges today from a handful of countries are welcome, but the world remains in the grip of a devastating global emergency. It demands bold, collective action. Today, global leaders of the G20 missed this critical opportunity,” said Alex Harris, Wellcome Trust’s Director of Government Relations.

“The moment has passed for warm words and piecemeal contributions – we need courageous, united leadership from countries that can most afford to help others. Next month’s G7 Summit is an historic opportunity to do this. It must not be wasted,” he added.

World Bank West and Central Africa Regional Director, Dena Ringold, says COVID-19 has exacerbated poverty on the African continent.

Africa’s delayed COVID-19 vaccine rollout could cost the continent close to $14-billion a month – and the situation could get worse.

World Bank West and Central Africa Regional Director, Dena Ringold,  said in addition to the severe impact of weak health systems, the pandemic was straining economies across Africa and has “exacerbated poverty” on the continent with tens of millions of people falling deeper into poverty.

Addressing a World Health Organization (WHO) African Region press briefing on Thursday,  Ringold said the delays in accessing COVID-19 vaccine on the continent is having significant impacts on economies.

“In addition to the loss of lives and human capital, we estimate that every month of delayed COVID-19 vaccination has the potential to cost the African continent close to $14 billion in lost GDP,” Ringold said.

The World Bank has recorded an increase in requests for financial support from governments and institutions in Africa and beyond, Ringold revealed, noting that the COVID-19 response has been the global financial institute’s largest and fastest response to a crisis in the history of the institution. 

“If I roll back to March of last year, our initial global package for health funds involved preparing in 100 days to help countries fight the pandemic through building capacity for testing, surveillance, and treatment. In Africa, this involves  $2-billion for 39 countries in Africa,” said Ringold, adding that they were “saving livelihoods through social protection estate, ensuring sustainable business growth and working to build more resilient recovery”. 

“We’ve been doing this in partnership with regional institutions such as the West African Health Organisation (WAHO) and the Africa CDC, which have been playing a critical role during the pandemic,” Ringold said. 

Paying for Vaccines

Matshidiso Moeti, WHO Regional Director for Africa, warns that a blockage on supplies are delaying Africa’s rollout of COVID-19 vaccines and risks curtailing plans to expand the continent’s rollout later this year.

Health Policy Watch recently reported African countries were reluctant to borrow funds to pay for COVID-19 vaccines,  but the Ringold revealed that the World Bank  has been supporting African countries with access to funding with which they can procure and deploy vaccine doses to their citizens.

As of Thursday 20 May, the World Bank had received requests from 36 countries in Africa for vaccine financing, amounting to close to US $2-billion.

The WHO also announced the COVAX Facility is now seeking other options towards addressing the global shortage of COVID-19 vaccines. 

Addressing a press conference on Thursday, Dr Matshidiso Moeti, the WHO Regional Director for Africa warned that a blockage on supplies and financial challenges are delaying Africa’s rollout of COVID-19 vaccines and risk curtailing plans to significantly expand the continent’s rollout later this year.

Moeti said deliveries to Africa through the COVAX facility ground to a near halt in May as the Serum Institute of India diverted doses for domestic use. Between February and May, the continent received just about a quarter – 18.2 million – of the 66 million expected doses through COVAX.

“As people living in richer countries hit the reset button this summer and their lives start to look normal, in Africa our lives will stay on hold. This is unjust,” Moeti said. “We are optimistic that vaccine availability will improve significantly in the second half of the year. We can still catch up and make up for the lost ground, but time is running out.”

Embracing Dose Sharing

To cover the wide vaccine supply gap that disproportionately affects African countries, Moeti recommended the adoption of dose sharing. 

“The supply gap can be closed if countries with surplus doses set aside a percentage of vaccines for COVAX,” said Moeti. 

She commended the decision of the US government to share 80 million doses with other countries, in addition to recent shipments of vaccines from France to Mauritania

“Dose sharing is key to ending the supply crunch and the pandemic as a whole, as no one is safe until everyone is safe,” said Moeti, further revealing that COVAX Facility is actively negotiating with other manufacturers of COVID-19 vaccines to diversify the portfolio while supporting the medium- to long-term scale up of manufacturing capacity. 

In spite of the call for more doses, Moeti admitted that funding for operational costs is also a critical barrier as only eight African countries have used up all their vaccines while over 20 countries have administered less than 50% of their doses.

Even though COVAX is providing its share of vaccines for free to lower-income countries, 60% of every dollar spent on delivering vaccines is needed for operations. 

“The World Bank calculates that on top of the money needed to buy enough vaccines to ensure adequate protection from COVID-19, another 3 billion is required to deliver the vaccines into the arms of people,” 

 

Johnson & Johnson’s single-dose COVID-19 vaccine

Johnson & Johnson will supply COVAX 200 million of its single-dose COVID-19 vaccines by the end of the year, according to a statement on Friday by Gavi, the Vaccine Alliance, announcing the advance purchase agreement.

The vaccine will be available to both COVAX members who buy their own vaccines and the COVAX AMC members. 

“Today’s agreement between Gavi and Johnson & Johnson means the COVAX Facility is able to offer participants yet another safe and effective tool against the pandemic. I welcome Johnson & Johnson’s commitment to equitable access and to expanding global manufacturing through external partnerships, which is something that will provide long-lasting benefits even after this pandemic is over,” said Dr Seth Berkley, CEO of Gavi.

Gavi and Johnson & Johnson are also discussing the possible supply of 300 million doses for COVAX in 2022. 

“As a one-dose vaccine, the J&J vaccine has particular relevance for places with difficult infrastructure, making it a very important addition to the portfolio.” 

“Our partnership with Gavi is the single greatest step we have taken to ensure our single-shot vaccine is accessible to everyone, everywhere. Our commitment today offers the potential to protect up to 500 million people from COVID-19,” said Paul Stoffels, Chief Scientific Officer at Johnson & Johnson

“COVAX now has agreements for eight vaccines and vaccine candidates – AstraZeneca/Oxford, Pfizer, Moderna, Novavax, Johnson & Johnson, Serum Institute of India (SII)’s Covishield, SII’s Covavax, and Sanofi/GSK – with the aim to expand to 10-12 vaccines in total, providing participants access to a diverse range of vaccines suitable for use in varied contexts and settings.,” said Gavi.

Gavi is also trying to raise at least an additional US$1.6 billion for the COVAX AMC to enable the supply of up to 1.8 billion doses of vaccine for 92 lower-income economies. 

Japan will be hosting the upcoming Gavi COVAX AMC Summit, bringing together world leaders, the private sector, civil society and key technical partners in a virtual event on June 2nd.

In addition to doses secured via agreements with manufacturers, Gavi and its COVAX partners the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization and UNICEF also call on the international community to share doses with COVAX immediately to help those countries that have been worst hit by current global supply constraints and urgently need to protect their most at-risk populations.

COVID-19 Deaths Could be 2-3 Times Higher than Officially Reported

Meanwhile, a new WHO estimate suggests that deaths from COVID-19 since the pandemic began may be 2-3 times higher than the 3.2 million deaths officially reported until 1 May 2021.

The estimates were contained in a new World Health Organization (WHO) World Health Statistics Report, released on Friday – which tracks a wide range of health statistics on disease, risks and other health indicators, across all 194 member states.  According to the report, while 1.8 milion deaths from COVID were officially reported in 2020, the real death toll last year was likely 1.2 million more than that, based on overall excess mortality rates for 2020, as compared to previous years. 

That leaves preliminary WHO estimates to suggest the total global excess deaths attributable to COVID-19, both directly and indirectly, amounted to around 3 million in the year 2020,  the report states.

And based on the data from 2020, the excess deaths recorded until now, may be 2-3 times higher than the 3.2 million deaths recorded until now – that is more than 6 million deaths, the report suggests.  The reason for the under-estimates lay in the fact that deaths from many people with pre-existing health conditions that make them more vulnerable to COVID diasese, may be recorded as dying from diabetes, heart, respiratory disease, or other such conditions – even if it was COVID that actually triggered their deterioration and death.

    

Cumulative confirmed COVID-19 deaths as of 1 May 2021, by region: a) in thousands; b) per 100 000 population; and c) by location

Cases Shifting From Wealthy to Low- and Middle-Income Countries 

In addition, while almost half (48%) of all reported COVID-19 deaths have occurred in the Americas, and one third (34%) in Europe, a shift in cases and deaths from higher- to lower-resource settings is now becoming evident, according to the report.

“ While high income countries (HICs) accounted for about 64% and 59% of the global monthly new cases and deaths, respectively, in January 2021, the shares dropped to 31% and 27%, respectively, in April 2021,” the report states.

In contrast, low- and medium income countries’ (LMIC) share of new global monthly cases rose from 8% in January 2021 to 37% in April 2021, and the share for new deaths from 8% to 22% between January and April 2021.

Meanwhile, of the 23.1 million cases reported in the South-East Asia Region to date, over 86% are attributed to India.  Until now, the WHO Region of the Americas and the European Region accounted for over three quarters of cases of the 150 million cases reported so far, with case rates per 100 000 population of 5999 and 5455 respectively. 

 

A patient getting tested for COVID-19 at the Paris Charles de Gaulle Airport in January 2021.

Though the COVID-19 pandemic has largely been a story of failure, strong preparedness of public health systems coupled with decisive responses have shown that it is possible to prevent and prepare for future disease threats, according to a new report.  

The report, conducted by Resolve to Save Lives, an initiative of Vital Strategies, highlights eight case studies that show the success of epidemics that didn’t happen, or whose impact was lessened, because of careful planning and strategic action. 

“No response is perfect and there’s no one size fits all approach, but taken together, these studies demonstrate that in moments of crisis, communicating clearly and effectively while working collaboratively with partners and communities can prevent epidemics, [guiding] our conversation on the future of global health security,” said Dr Tom Frieden, President and CEO of Resolve to Save Lives on Thursday.

The report reviews how the trajectory of an epidemic can be altered when a country invests in and prioritizes preparedness for infectious diseases outbreaks, such as Uganda and Brazil. 

Uganda’s Rapid Response and Mobilization Against Ebola Outbreak

Surveillance for Ebola Virus at the border between Democratic Republic of Congo and Uganda.

Within days of the Ebola outbreak being declared in the Democratic Republic of the Congo (DRC) in August 2018, Uganda was able to rapidly mobilize its response teams to prevent further infection. 

Within weeks, Uganda opened multiple Ebola Treatment Centers and rapid testing laboratories near the DRC border, where border screenings were conducted for all people entering the country. 

By November 2018, the Ugandan government had vaccinated nearly 5,000 health care workers and response staff.

This was all done before any cases had been identified in Uganda. 

Ugandan Minister of Health Dr Jane Ruth Aceng attributes the country’s strong outbreak response to collaboration and partnerships across sectors.

“Strong partnerships for support, both financially and also technically, as well as stakeholder engagements are critical in responding to any public health emergencies,” said Aceng.

Brazil: Mass Vaccination Against Yellow Fever 

Brazil’s successful response to containing yellow fever in 2019 produced dramatic results, with only 85 yellow fever cases and 15 deaths reported.

Brazil’s successful response to its 2016 – 2018 yellow fever outbreak was due to its scientific expertise on the disease and its role as one of the largest producers of the yellow fever vaccine – making the country well-positioned to address its yellow fever outbreak. 

However, at the time of the outbreak, vaccine supplies were low. 

To manage a large number of vaccinations needed amid a vaccine shortage, health officials requested additional supplies from an international stockpile, and stretched supply further by using partial doses of the vaccine.

Studies have shown that one-fifth of a standard dose can provide up to a year of immunity, and can be beneficial for containing outbreaks. 

Health officials also prioritized surveillance of yellow fever outbreaks among animals, which would provide advance warning of where human cases would later appear. 

By the end of the 2019 yellow fever season, these measures had produced dramatic results, with only 85 yellow fever cases and 15 deaths reported. 

Highlighting Brazil’s successful response to containing yellow fever, Dr Sylvain Aldighieri advocated for increased investments in healthcare workers – a critical issue, he said, should be stressed in the upcoming G-7 and G-20 Global Health Summits.  

“We have this population of healthcare workers dealing with a day-by-day battle for more than 16 months.”

Investment in healthcare workers includes Personal Protective Equipment, vaccinations, training, and adequate ratio of staff-to-patients.  

Aldighieri pointed out that integrated and strong primary health care was also what aided Brazil during its outbreak.

“If you have a strong primary health care system it avoids a lot of trouble in the following steps of response.”  

Seven-One-Seven Approach to Pandemic Preparedness

From these case studies, and from existing recommendations, Resolve to Save Lives has proposed a goal of seven-one-seven – identifying any suspected outbreak within seven days of its emergence, responding rapidly through investigation and reporting within one day, and establishing an effective response within seven days. 

This type of goal, said Frieden, will provide impetus and accountability to make substantial and sustained financial, technical, and political investments needed to improve global health and our capacity to find, stop, and prevent future pandemics.” 

“The COVID-19 pandemic has reinforced the need to work together. We’re all connected. And it’s on all of us to prevent epidemics.” 

Effective Global Health Governance and Collective Investment in Preparedness Needed 

Recommendations for addressing future pandemics and looking beyond COVID-19 through more effective global health governance were also considered, in light of the recently released Independent Panel Report

“We need a strong World Health Organisation (WHO), but we [also] need a more independent WHO that could operate independently and actually make decisions faster, said Dr John-Arne Rottingen, Ambassador for Global Health at the Norweigian Ministry of Foreign Affairs.

He emphasizes that though achieving this type of leadership is a ‘tricky balance’, it demonstrates the need for strong public health capacities not just in the WHO, but across the globe.

This is important in developing countries, which have limited resources to prepare for disease outbreaks. Though countries would ideally like to focus on themselves and their key priorities, the ‘collective investing’ in the health systems of low-and-middle-income countries would be a ‘public good’, not just at the national level but also at an international level, added Rottingen. 

“It’s good for everyone. We can avoid infectious disease threats and it’s a collective investment,” he said, noting all countries should contribute, from high-income to low-income countries, investing both domestically and to collective finance mechanisms. 

As seen with the vaccine nationalism of the current COVID-19 pandemic, countries primarily focus on the needs of their people before considering the ripple effects of disease outbreak in other countries. 

Investment towards countries with ‘lower purchasing power’ would contribute to pandemic preparedness. 

“We need to demonstrate that we can deliver equitable access in this pandemic; if not we will not be trusted in the future.” 

Image Credits: Flickr – International Monetary Fund, WHO Afro, Matt Taylor, WHO.

Dr Ahmed Al Mandhari, WHO Regional Director for the Eastern Mediterranean, at a press conference on Thursday.

The hostilities between Israel and Hamas over the past 10 days have caused significant damage to the health system in Gaza, putting the Palestinian population at risk of increased spread of COVID-19 – after six weeks in which new cases had been in sharp decline.

The health system in Gaza is now facing severe shortages of essential medicines and supplies and it’s only COVID test facility was destroyed. The closure of border crossings has restricted the entry of medical supplies – although Israel said late Thursday night that it would begin opening the borders to humanitarian aid if a cease-fire with Gaza’s Hamas authorities, due to take effect at 2 a.m. local time, holds. 

“WHO calls for the urgent facilitation of humanitarian access to the Gaza Strip to allow entry of essential medical supplies, referral of patients to facilities outside the Gaza Strip, and passage of medical teams and humanitarian personnel,” said Dr Ahmed Al Mandhari, WHO Regional Director for the Eastern Mediterranean, at a press conference on Thursday that came just ahead of the Egyptian-brokered cease-fire agreement with Israel. Hamas began a missile assault on Israeli cities 10 May, in reprisal for Israeli moves to evict several Palestinian families from homes in East Jerusalem and Israeli police clashes with Palestinians around the city’s Al-Aqsa Mosque, Islam’s third holiest site.  Israel responded with heavy aircraft raids over Gaza, targeting offices and high-rise buildings of strategic importance, and damaging a vast labyrinth of underground tunnels, which Israel says were used by Hamas fighters hide from Israeli attack.  

Over 245 deaths and 6,700 injuries have been reported in the Gaza Strip and West Bank during the violence, according to WHO, while in Israel, 12 people including two children have been killed.

What’s more, however, the aerial bombing of Gaza damaged or destroyed 19 health facilities, a desalination plant that supplies clean water to 250,000 people, and Gaza’s main COVID-19 testing laboratory. 

Gaza, which has been under an Israeli blockade since the Islamist Hamas Party took control of the enclave in 2007, has seen intermittent flareups with Israel that have grown in intensity as Hamas gained more missile power to hit deeper into Israeli territory. Neither Hamas nor the Israeli government recognize each other as legitimate authorities.

More than 90 attacks on health care workers have been recorded in the West Bank and Gaza Strip, with 21 recorded in the Gaza Strip and 70 in the West Bank, Mandhari said, adding that, “WHO also calls for the immediate cessation of hostilities and an end to attacks that either directly or indirectly impact health care in the occupied Palestinian territory.” 

In the Israeli-occupied West Bank, the Palestinian Authority, which is recognized by Israel, has limited self-rule, under the terms of the 2003 Oslo Accords. However, the past two weeks also saw a wave of West Bank Palestinian demonstrations and clashes with Israeli troops in support of the Hamas as well – creating barriers to access of health facilities, particularly in East Jerusalem, which is under Israeli control.

The WHO situation overview of casualities and damage caused since 7 May in the occupied Palestinian territories.

Damage to Health and Water Facilities – Interrupts Essential Health Services and COVID Testing and Vaccinations

In Gaza, the only functioning COVID-19 testing lab, housed in the Al-Rimal health clinic in Gaza city, was damaged on Monday by an airstrike. It processed over 2,500 tests per day, as well as administering COVID vaccinations and providing other essential health services. 

The damage to water desalination plants and water sanitation hygiene (WASH) infrastructure increases the risk of waterborne diseases and impacts hygiene, which is a central component of COVID-19 public health measures, said WHO officials.

Along with that, 46% of essential drugs and 33% of essential medical supplies also are out of stock in Gaza. And heavy damage to roads, including the main road to Shifa Hospital, one of Gaza’s largest hospitals, is obstructing ambulance access.

The health impacts of the escalation in violence in the occupied Palestinian terriories.

WHO has procured and delivered US$200,000 worth of essential medicines to hospitals in East Jerusalem, and has a convoy ready with US$500,000 worth of rapid diagnostic tests, equipment, and medical supplies destined for the Gaza Strip. 

“The fighting must stop immediately. Until a ceasefire is reached, all parties to the conflict must agree to humanitarian pause to ensure access into and out of Gaza for humanitarian staff and critical goods…to allow for safe movement, and for the delivery of assistance,” said Dr Rik Peeperkorn, WHO Head of the Regional Office for the West Bank and Gaza Strip.

“We need a ceasefire, we need a humanitarian pause,” said Dr Richard Brennan, WHO Regional Emergency Director for the Eastern Mediterranean. “We need the humanitarian access. We want all the crossings to be opened to let the aid in and let the sick and injured out.”

“If we are speaking about the current political and security situation in the region and in the occupied Palestinian territory in particular, there is no health without peace,” said Mandhari.

Some 75,000 people have been displaced by the violence, with 47,000 seeking shelter at 58 schools run by the UN Relief and Works Agency for Palestine Refugees in the Near East. The overcrowding at these shelters could facilitate the spread of the SARS-CoV2 virus, WHO officials said. 

COVID Figures Likely Don’t Reflect Local Situation 

Both the West Bank and Gaza were just coming out of a third COVID wave when the violence escalated. The damage to health infrastructure, testing capacity, and water sanitation facilities will likely cause the pandemic to worsen, officials said. 

Even before the hostilities started on 10 May, cases were sharply declining from a peak of 2,500 new cases in April, to less than 600 as of May 10. And that trend has continued over the past week. However, officials are concerned that recent data is misleading, due to the current absence of testing and tracking procedures, particularly in Gaza. 

About 5.4% of Palestinians in Gaza and the Occupied West Bank have received at least one dose of a COVID-19 vaccine – doses obtained through the WHO co-sponsored COVAX initiative or from donations.   

This is in stark contrast to Israel’s national vaccination campaign, which has immunized 62.8% of the population with at least one dose. 

WHO currently has a convoy of 10,000 more Sinopharm COVID-19 vaccines waiting to enter Gaza as soon as possible to provide jabs to more of the population, said officials.

“Overall there is still a huge shortage of vaccines in the occupied Palestinian territories and the coverage is still way too low,” said Peeperkorn.

Dr Rik Peeperkorn, WHO Head of the Regional Office for the West Bank and Gaza Strip.

WHO announced that US$7 million will be needed for the health response in the occupied Palestinian territories over the next six months. 

The plan is to first provide assistance to Gaza for acute health needs and then focus on rebuilding the health infrastructure and strengthening the health system to ensure a functional primary health care system is established once again, said Peeperkorn.

In the midst of the ongoing conflict, a heated political debate is expected to take place in the upcoming World Health Assembly (24 May -1 June) on a draft resolution on the health conditions of and assistance to provide the Palestinian population.  Israel has long complained that setting the resolution as a separate agenda item for the WHA represents disproportionate and politicized treatment of the Palestinian issue – as compared to the many other humanitarian flash points around the world – which do not get the same prioritization at the WHA forum.

Image Credits: WHO.

With an agenda that is more packed than ever – and razor sharp political crises from Gaza to Taiwan to Myanmar also coming to the fore – will the upcoming World Health Assembly prove to be the decisive moment that it should be for global health? 

Now, more than ever perhaps, huge tensions and inequalities plague the global health scene – with new COVID cases in high-income countries slowly declining, and international borders reopening, while India as well as other low-income countries in South East Asia and the Americas battle continue to battle huge case counts and death tolls. 

Against that landscape, however, some far-reaching recommendations for reform that will be on the table this year could make a big difference, said a group of high-level global health voices at an “Introduction to WHA 74 session,” sponsored by the Global Health Centre of the Geneva Graduate Institute.  

They referred to proposals by The Independent Panel for a Pandemic Treaty; limiting the Director General’s term to one five-seven year stint to remove the position from political influences; and the granting of stronger investigative powers to visit countries and publish data on outbreak threats, said Julio Frenk, former minister of health for Mexico and president of the University of Miami, speaking at the event.  

”The main problem until now has been that the member states by design or by behaviour have weakened the operation of their own organisation,” said Frenk at the session, which also featured Ellen Johnson Sirleaf, co-chair of The Independent Panel on Pandemic Preparedness and Response, Gro Harlem Brundtland, former Prime Minister of Norway as well as WHO director general Tedros Adhanom Ghebreyesus, and Joy Phumaphi, of the UN Secretary General’s Every Woman, Every Child Accountability Panel.  

Julio Frenk, Former Minister of Health of Mexico and President of the University of Miami.

Limiting the director-general’s tenure to just one term in office would be a “major step” towards a more independent and depoliticized WHO – “so as not to have a director who is also campaigning for re-election,” Frenk asserted. 

Added Brundtland, who gained worldwide acclaim for key health reforms that she instituted at WHO during her 1998-2003 tenure, “A seven year term is a better choice. Because then, no leader of WHO, in the future will be in the situation to be lobbying to be reelected.”

But the inequalities in access to vital COVID-19 vaccines and other health products, is the bigger pandemic picture that must urgently be addressed, she said.

“The world again was taken unprepared. The vaccine situation is an illustration that a whole-of-government approach, whole-world approach at the highest level is not there.”

“I was shocked when we realized that not only with regard to vaccine distribution, but also PPE, therapeutics, nothing could be done, frankly, by our financial institutions who serve the developing countries, because they have no mechanism for supporting global public goods.  This illustrates how important it is that we pursue these kinds of recommendations – broadly speaking, to be prepared.” 

Reforms that stimulate more equitable access could be stimulated by the creation of a high-level Global Health Threats Council – annother recommendation emerging out of the Independent Panel: 

“A Global Health Threats Council is something I think needs to be institutionalized – with a financing mechanism that is not based on ODA [donor aid] and the idea of giving gifts to countries – but rather a responsibility of all countries, based on ability to pay,” Brundtland said.

Gro Harlem Brundtland, Co-Chair, Global Pandemic Preparedness Monitoring Board.

Intellectual Property Waiver – A Novel Suggestion

Ellen Johnson Sirleaf, former president of Liberia and co-chair of The Indepdendent Panel.

As for the debate over current proposals by WHO and many other global health advocates to implement a World Trade Organization waiver on intellectual property (IP) rights for COVID health products, for the duration of the pandemic, Johnson-Sirleaf  suggested a novel proposal.  She said that high-income countries flush in vaccines should commit to turning over at least 1 billion doses to the COVAX global vaccine facility by 1 September – and two billion doses by 2022, supported by more agreements for voluntary licensing by big pharma of manufacturing in the global south, and tech transfer agreements. And in the absence of such commitments, then WTO members should rally around the proposed agreement to waiver IP rights set out in the WTO TRIPS Agreement altogether.

“We feel if that doesn’t happen, there should be a waiver of TRIPS,” she declared. ” So that, that can come into force with immediate effect. What this will require is that the major vaccine producing have the power to make that happen.”

Sirleaf said she was looking to Friday’s G-20 Global Health Summit, hosted by Italy and the European Commission, for clear responses.

“The Independent Panel’s impact is a moral force and setting the expectations, but we have very little leverage. It is the inter-governmental forces such as the G-20 and the G-7 that are the useful institutions to create the peer pressure, and to promote a sense of momentum. The key message from us the the scale of vaccine distribution needed.  With 1 billion doses by September. Not 10 million. Not 100 million… we need 1 billion by that date. Anything short of this, will simply not be enough to start slowing the pandemic, towards eradication.”

Increasing Annual Contributions to WHO 

Another key reform with meaning would be increasing the regular annual contributions to WHO from member states, beginning with a gesture by the United States to reverse the 1999-era  Helms/Biden Act – which froze it’s regular WHO contributions in time, emphasized Frenk.   

“We’ve got to change the funding, there’s no national health agency that could function, if 80% of its funding came from voluntary contributions.  

“If this is really the organisation of member states, then member states need to pay for their organisation,” declared Frenk at the session. “Therefore, the increase to two-thirds of the budget coming from assessed contributions with an equitable formula. That has to happen, and the United States needs to lead the way. 

“Because the process that led us to the current situation was an amendment to a law that bears the name of the current president, President Biden, it’s called the Helms/Biden Act, and it froze the nominal amount of assessed contributions. And since then, the proportion that’s covered by those assessed contributions has been coming down to be now, very very insufficient.” 

In RealPolitik Prospects for Key Reforms are Dim 

However, in the realpolitik of WHA negotiations, the changes that key reform measures might receive the consensus vote they need for approval remains dim to doubtful, people close to the organisation told Health Policy Watch. 

“On the single term DG issue, there’s not a chance that it can be considered in operational terms at this World Health Assembly because formally it does not fall within the scope of the existing items on health security. It requires reopening the issue of DG elections,” said one diplomatic observer, adding, “and I doubt that that reform – as objectively desirable as it can be – will ever pass because it would deprive key countries of influence and control over the DG if he/she cannot run for re-election.” 

Prospects for a Pandemic Treaty – most likely to take shape as a Pandemic Framework Convention supervised by the WHO if it happens at all – appear to be equally troubled by opposition from major countries such as the United States, Russia and Brazil.  The unusual set of allies have argued that negotiations over a treaty would be too time-consuming to conduct right now, as the world remains in the midst of battle with COVID-19. 

This is despite support the pandemic treaty concept has received from some two dozen other G-20 countries, as well as the WHO.  

That ambivalence has led to the circulation of two versions of a draft WHA resolution on follow-up to the Independent Panel’s recommendations. According to one version, WHA member states would explicitly agree to begin negotiations towards a legal treaty or convention. But the other version would merely agree upon the creation of a working group to take forward the recommendations of the Independent Panel as well as those of two other investigative committees, exploring gaps that emerged during the pandemic in the existing International Health Regulations as well as WHO’s own emergency response 

“I understand that there are negotiations going on now on whether and how to combine them –  given the fact that the US, Russia, Brazil and some other big countries are against starting negotiations now and want to kick that issue down the road,” said one observer. 

Geopolitical Rifts Also Threaten Unity 

Gian Luca Burci, Professor of International Law at The Graduate Institute, and former WHO legal counsel.

Along with the burning global health issues that need to be faced, some serious geopolitical rifts are likely to disturb the proceedings of the WHA – already from the first day of the Assembly. 

That will be when member states debate a proposal to admit Taiwan as an observer to the WHA – after freezing it out since 2016.  The controversial proposal is now supported by 13 leading member states, including G-7 countries. 

There will also be an equally heated debate on which government should represent Myanmar. Since the military coup – two claim that role – the junta now in power and a shadow, opposition government. 

Finally, the thorny issue of the Palestinian humanitarian situation in Gaza will also be debated – after being front and center in the news over the past 10 days, following intense exchanges of missles and fire power between the Hamas-controlled Gaza strip and Israel. 

”There will be political issues and issues of  participation,” said Gian Luca Burci, a professor of international law at The Graduate Institute and a former WHO legal counsel.  He noted that politically-laden procedural hurdles that will  have to be navigated in addressing all three issues. 

“Thirteen states have  again made invitation for Taiwan to attend the Health Assembly as an observer, ” he said. “There will certainly be a very difficult, very controversial debate and vote on the draft resolution on assistance to Palestinian population in the occupied Palestinian territory in view of the current circumstances. There will be two governments that would like to represent Myanmar. One is a military government that has taken power in the coup in February, and the other is the civilian government deposed. Both presented credentials, and these will need to be considered in the credential committee. 

“On the positive side, the WHA will invite the Holy See, which has already been observing the Health Assembly for many years at the invitation of the director general, to be formally invited to participate as a non member observer state.” 

Big Agenda – Modest Expectations  

Dr Tedros Adhanom Ghebreyesus, WHO Director General and moderating John E. Lange, Senior Fellow of Global Health Diplomacy at the United Nations Foundation, at the Global Health Centre event.

“This year’s Health Assembly is arguably one of the most important in the history of WHO, and the COVID 19 pandemic means we will once again gather, virtually – but that has not limited the scope or importance of the discussions,” said WHO Director General Dr Tedros, in a video-cast message at the opening of the Global Health Centre panel discussion. 

“In fact, this year, We have one of the heaviest agendas on record.”

Actions taken in response to the recommendations of the Independent Panel and two other investigative panels, which have reviewed WHO’s own internal emergencies response and the International Health Regulations, “ will have far reaching ramifications for the Global Health architecture of the future, “ he noted. 

Items on “the global health workforce, and accountability issues around the prevention of sexual exploitation and abuse,” are other issues of particular note, Tedros added. 

Despite the big agenda, Burci has modest expectations.

“This crisis is quite different from Ebola and so on.  There’s (as of now) hardly any agreement on anything except at a high level of generality.  Besides advocating for big changes and criticizing states’  short-sightedness, there should be some serious analysis why this is the case – because it may show more systemic changes in the world that we need to understand.

“The upside is probably that the WHA will set up an intergovernmental process to at least discuss the various reviews and sketch some ways forward.  It sounds like a talk shop, but states need to be brought back to the centre of the policy debate within WHO rather than through the usual G7/G20 clubs.  

Memories Are Short 

Suerie Moon, Co-Director of the Global Health Centre,

Along with being a milestone moment, this year’s WHA also has one of the largest agendas ever on record, noted Suerie Moon, co-director of the Global Health Center at the Geneva Graduate Institute, who moderated the panel. 

“There are about 70 agenda items on the WHA agenda, beyond COVID-19 – and this is a timely reminder that who is more important for the health of all of us, than it’s ever been.” 

“Clearly there’s no shortage of challenges, nor potential solutions to address some of these weaknesses, but there’s also no guarantee that we will seize this moment, and that we will seize this moment to strengthen the WHO.” 

 “This pandemic is not yet over, and yet we know that memories are short. Opportunities are limited to fix the global system that COVID has shown is deeply inadequate,” said Moon.  

“And whether or not COVID becomes a game changer will depend on at least four things. I would say political leadership, political courage, political wisdom and political mobilization.”

Editor’s Note- Health Policy Watch is a media partner in the Geneva Health Centre’s series of WHA week events. 

 

Image Credits: Global Health Center.

 

Inspecting a pig’s health in Busia, western Kenya in 2010. Livestock often serve as a bridge for the transmission of zoonotic diseases.

A new international expert panel launched by four international organisations on Thursday aims to blunt the emergence and spread of zoonotic diseases through better understanding of human, animal, and environmental interactions that enable animal-borne diseases to break into human populations.  

The One Health High Level Expert Panel will advise the World Health Organization (WHO), the Food and Agriculture Organization (FAO), the World Organization for Animal Health (OIE), and the United Nations Environmental Programme (UNEP) on developing a long-term global plan of action to avert outbreaks of diseases, such as Ebola, Zika, and COVID-19.

The panel was borne out of the COVID-19 pandemic and was proposed by Germany and France at the Paris Peace Forum last November. 

“The rapid establishment of this panel shows the commitment of the international community to learn from all lessons of the current health crisis,” said Jean-Yves Le Drian, France’s Minister for Europe and Foreign Affairs, at a press conference on Thursday.

“The COVID-19 pandemic is a powerful demonstration that human health does not exist in a vacuum, and nor can our efforts to protect and promote it,” said Dr Tedros Adhanom Ghebreyesus, WHO Director General. 

Dr Tedros Adhanom Ghebreyesus, WHO Director General.

“The close links between human, animal, and environmental health, demand close collaboration, communication and coordination between the relevant sectors,” said Tedros.

Zoonotic Diseases as a Major Neglected Health Risk Area

Some 75% of all emerging infections are transmitted from animals and 60% of the known infectious diseases in humans can be transmitted by animals through direct contact or through food, water, and the environment. 

Neglected zoonotic diseases kill at least two million people annually, mostly in low- and middle-income countries.

Health threats are becoming increasingly complex due to the interdependent relationships humans have with animals and the environment for food, livelihoods, and wellbeing. Factors include poaching and ecosystem destruction that brings people into closer contact with wild animals as well as commerce in wild animals for food and traditional medicines.  

Zoonotic diseases, including rabies, zoonotic influenza, Ebola, and Rift Valley fever, as well as food-borne diseases and antimicrobial resistance, have major impacts on health, livelihoods, and economies.

Emerging pathogens are crossing the animal-human barrier with increased frequency or greater impact, potentially due to environmental changes in rural and urban areas. In rural areas, deforestation can lead to increased human contact with wild animals that harbour and transmit diseases.

In urban areas, the crowded conditions used to house animals in industrialised livestock production systems allow infections to easily mutate and jump to human hosts. 

Certain wild animals – including rodents, bats, carnivores and non-human primates – are most likely to harbour zoonotic pathogens, with livestock often serving as a bridge for transmission. 

Global demand for animal meat has risen by 260%, which has prompted large scale industrialised livestock production and is exacerbating the risk of spreading zoonoses.

Risk of Zoonotic Epidemics Rises as Humans Increasingly Cause Environmental Degradation

The rising trend in zoonotic diseases is likely being driven by increased demand for animal protein; unsustainable farming practices; increased exploitation of wildlife; unsustainable use of natural resources accelerated by urbanization and extractive industries; increased travel; changes in food supply; and climate change, according to a UNEP report published in July 2020. 

“As we exploit more marginal areas, we are creating opportunities for transmission,” said Eric Fèvre, Professor of Veterinary Infectious diseases at the University of Liverpool, in a press release. “There is an increasing risk of seeing bigger epidemics and, eventually, a pandemic of the COVID-19 type as our footprint on the world expands.”

Antimicrobial resistance (AMR) is another growing public health threat that is linked to the use of antibiotics in livestock and agriculture. The overuse or misuse of antibiotics in food-producing animals can lead to antimicrobial resistant infections in humans that cause longer illnesses, more frequent hospitalizations, and treatment failures. 

Testing for antimicrobial resistance at the Liverpool School of Tropical Science.

Currently, at least 700,000 people die each year due to drug-resistant diseases. 

“We need, among other things, to break down disciplinary and organisational silos, to invest in public health programmes, to farm sustainable, to end the over-exploitation of wildlife, to restore land and ecosystem health and to reduce climate change,” said Jimmy Smith, Director General of the International Livestock Research Institute, in the UNEP report. 

Most efforts to control zoonotic diseases to date have been reactive instead of proactive. The COVID-19 pandemic has demonstrated that the root causes of novel zoonotic diseases need to be addressed in order to prevent future outbreaks, said officials at the press conference. 

The purpose of the new expert panel will be to consider the impact of human activity on the environment and wildlife habitats and its link to zoonotic diseases. 

The One Health approach is widely considered the optimal way to respond to and prevent future pandemics, as it unites medical, veterinary and environmental expertise and recognises the links between the health of people, animals, and the environment.

The launch of the One Health High Level Expert Panel is the latest attempt from the tripartite alliance to promote the One Health approach.

Panel will Take ‘One Health’ Concept to the Next Level

While the One Health concept is not new and the tripartite alliance between WHO, FAO, and OIE was formed over a decade ago to develop the concept, “the high level expert panel is a much needed initiative to take it to the next level,” said Tedros. 

“The high level expert panel will advise us on how to bridge the gaps between sectors, connecting veterinary and human medicine, and environmental issues and to address the challenge of implementation at both the global and country level,” Tedros added. 

The 26-member panel held its inaugural meeting on Monday, in which four working groups were established. The working groups will focus on implementing “One Health”; extracting best practices from existing global programmes and projects; establishing surveillance and early warning systems; and identifying spillover factors. 

Dr Thomas Mettenleiter, co-chair of the One Health High Level Expert Panel.

The next meeting will take place before the summer and the panel plans to release its first tangible results by the fall, said Dr Thomas Mettenleiter, co-chair of the expert panel. 

The initial efforts of the new body will be to examine the factors that lead to the transmission of a disease from animals to humans, develop risk assessment frameworks, and identify capacity gaps to prepare for and prevent zoonotic outbreaks. 

“This panel will contribute to advancing the One Health agenda, by helping to better understand the root causes of disease emergence and spread, and informing decision-makers to prevent long-term public health risks,” said Dr Qu Dongyu, Director General of FAO.

Dr Qu Dongyu, Director General of FAO.

It will “provide robust scientific analysis…and evidence-based recommendations on policy approach[es] with long term relevance that will reduce the risk of emergence of zoonosis with pandemic potential,” said Dr Monique Eloit, Director General of the OIE. 

“The work of the panel will help us advocate for bold policy measures and investments to reduce the risk of future pandemics, and to change harmful practices that threaten us now and in future generations,” said Tedros. 

France Calls for “Other Sweeping Measures”

At the press conference on Thursday, France announced its commitment of €3 million to support the secretariat of the panel.

“We hope that the creation of this panel…will be followed by other sweeping measures,” said Jean-Yves Le Drian.

Jean-Yves Le Drian, France’s Minister for Europe and Foreign Affairs.

Pandemic-related reforms and new measures will be debated at the G-20 Global Health Summit, which will take place virtually tomorrow, and at the upcoming 74th World Health Assembly (24 May-1 June).

A draft ‘Rome Declaration’ that will be issued at the G-20 meeting on Friday, calls for a “One Health approach…to address threats emerging at the human-animal-ecosystems interface, and antimicrobial resistance.”

Hot on the agenda for the World Health Assembly are talks for a “pandemic treaty” to better prevent, prepare and respond to infectious disease outbreaks. If such a treaty were to exist, there would be pressure from numerous experts to take a One Health approach. 

Image Credits: Nettverk for dyrs frihet / Net. for Animal Freedom, ILRI / Charlie Pye-Smith, WHO, Flickr – UK Department for International Development.

pandemic

Conquering the COVID-19 pandemic will inevitably be the main topic for discussion at the impending 74th session of the World Health Assembly, which begins Monday, 24 May. Global health experts weighed in this week at a series of briefings on what to expect from at the upcoming event. Geneva Solution’s Pokuaa Oduro Bonsrah reports:

The annual World Health Assembly will open online on Monday, with ministers of health from the World Health Organization’s 194 member states tasked with wading through a heavy agenda dominated by how to fix the COVID-ridden global health system and step up global response to future crises. 

“It is time to elevate the threat of pandemics at the level of other existential threats such as nuclear accidents,” Dr Joanne Liu, former International president of Médecins Sans Frontières (MSF) and a member of the Independent Panel for Pandemic and Preparedness Response (IPPR), said in an interview with Geneva Solutions. 

“This is why we call it a “Chernobyl moment in the 21st century”. If we want to move fast and in a sustainable way this scale up is necessary.” The findings of the independent review panel, set up by the WHO to examine the international COVID-19 response and published last week, will be at centre of discussions next week. 

What is the WHA and Why is it Important?

WHO Director-General Dr Tedros Adhanom Ghebreyesus delivers the closing speech for the World Health Assembly, 2019

As the decision-making body of the World Health Organization (WHO), the annual WHA meet-up gives member states the opportunity to chime in on WHO’s policy direction, governance, budget spending and health priorities.

The eight-day assembly, while officially hosted in Geneva, will take place online for the second year in a row, with over 2,750 people already registered to the event including civil society organisations. While COVID-focused, the Assembly will also tackle a range of health issues from antimicrobial resistance to non-communicable diseases. Exhibiting the largest agenda ever, with over 72 items, global health experts shed light on areas that they expect will dominate this 74th session.

Pushing for Legally Binding Instruments to Fight Pandemics

Charles Michel, President of the European Council

Hot on the agenda are talks for a “pandemic treaty” or convention to better prevent, prepare and respond to infectious disease outbreaks. First floated by the European Council’s president Charles Michel in November, the idea has so far been backed by 25 countries, including the WHO. However some of the world’s major powers, including the US and China, have yet to commit. 

The organisation’s treaty-making powers have only been used once in its history to create the Framework Convention on Tobacco Control (FCTC); it is one of three decision-making tools the WHA has at its disposal, including its recommendation powers used the majority of the time, and its regulation tool that formed the basis of the International Health Regulations.

Speaking at a press briefing on Wednesday, Steven Solomon, principal legal officer at the WHO said: “What’s so interesting about this upcoming World Health Assembly is that all three tools will be considered for possible needs in response to the pandemic,” Solomon noted.

Antoine Flahault, director of the Institute of Global Health at the University of Geneva

Although the intricacies of the treaty are yet to be discussed, Dr Antoine Flahault, director of the University of Geneva’s Institute for global health, said a pandemic treaty should guarantee the power of investigation from an early stage.

“With COVID, it would have been useful to have a pandemic preparedness treaty to allow full, independent, rapid investigation into the inception of the pandemic. As we have seen in the China example and the investigation in Wuhan, we missed the chance to scrutinise the origins of the pandemic early on, which has potentially devastating effects” said Flahault, also speaking at the briefing.

Bearing this in mind, when convening a Public Health Emergency of International Concern (PHEIC), the formal declaration by WHO of “an extraordinary event which is determined to constitute a public health risk to other states through the international spread of disease”, the pandemic should be treated in a similar way to the treaty on the non-proliferation of nuclear weapons or World Trade Organizations directives, “giving it the same level of power and impact, so that when violated sanctions are imposed,” he added.

In Liu’s opinion this should go beyond agreeing on rules, and would instead like to see more “action and accountability.”

Cementing the Power of the WHO to Fight Off Future Health Crises and Eradicate the Current Pandemic

The Independent Panel Team

At a more informal level, countries have been working amongst themselves to agree on how to strengthen WHO preparedness and response to health emergencies, and it is hoped recommendations emerging out of these discussions will be made at the WHA, according to Solomon.

In the recent report by The Independent Panel, co-chaired by the former prime minister of New Zealand, Helen Clark, and president of Liberia, Ellen Johnson Sirleaf,  weak links were found in both preparedness and response – including a broken global emergency alert system, a hesistant WHO and patchy country responses.  Lessons from previous pandemics were not incorporated either, the panel found, citing, for example, the 2009 H1N1 influenza response. 

Along with supporting a Pandemic Treaty, as a way to make pandemic response a higher political priority back by an stronger legal mandate, the Independent Panel also urged that WHA member states push for the creation of a Global Health Threats Council, with plans to put the idea forward at the United Nations General Assembly (UNGA) in September.

“By having this at the highest level it gives it the attention it deserves. We want it at the UNGA after discussion at the WHA, giving heads of states and governments the opportunity to take up ownership it needs,” said Liu.

WHO’s Political Independence

Current WHO Director General Dr Tedros Adhanom Ghebreyusus

In order for the WHO to flourish and have the appropriate means to address the current and future pandemics, the global health experts also believe the political independence of the WHO also needs to be frankly  discussed as  a top priority at the WHA.

This includes a recommendation by the Independent Panel that member states limit the WHO director general’s tenure to just one term of no more than seven years – as compared to the system today, whereby he can hold office for up to two, five year terms. 

The hope is this would shield the WHO chief from political pressures during his tenure – and from pressures to collude  with certain member states in order to secure re-election for a second term.

Instead of a seven-year non-renewable-term, Flahault, however, advocates for a five-year non-renewable term. Still, the main message of independence and autonomy  remains the same.

Governance and Funding Without Strings Attached

Bill Gates, chair of the Bill and Melinda Gates Foundation

When it comes to coughing up cash, member states have stalled on increasing their contributions. Philanthropic actors such as the Bill and Melinda Gates Foundation have filled the void by becoming major funders of global health and the WHO; but this has in turn been met with criticism from civil society as well as some member states for giving external actors too much influence over the organization.

Both Flahault and Liu say the blame should be shifted from philanthropies – to that of countries that are not playing their role. “The total WHO budget for example is hardly above the budget of most teaching hospitals in high income countries, such as University of Geneva Hospital,” explained Flahault.

Read also: Bill Gates is ready to spend more on global health – governments should too, says foundation official

The WHO should be robust and agile enough to anticipate, and respond to, health crises. As such the question of reform, including of its governance structures, also is a looming issue at WHA meetings.   

But for Flahault institutional reform can suck up a lot of energy and time – without yielding enough results. Instead, he says that the focus should be on giving the WHO the mandate to coordinate and lead on health matters.

The Question of Vaccine Equity

Civil society groups demonstrate outside embassies of the United States, United Kingdom, Australia, Canada, Brazil, and other countries which oppose a temporary WTO patent waiver on COVID-19 health products.

“One of the priorities of the WHA to be discussed with urgency is the production of vaccines, technology transfer and patent waivers”  Flahault also said.

While the final decisions around a proposed intellectual property waiver on Covid vaccines and other health products will be made in the World Trade Organization, WHA statements and discussions will also have an influence. 

The WHA debate will also come on the heels of a critical Global Health Summit of the Group of 20 (G-20). Outcomes of Friday’s G-20 meeting, hosted by the Italian government and the European Commission, will also set the texture of high-income country positions in the WHA proceedings.  

A draft G-20 “Rome Declaration” seen by Health Policy Watch,  makes no mention of the proposed IP waiver – referring only to the potential for “voluntary… technology transfer and licensing partnerships.”  And although the leaders of the G20 will also affirm their support for the WHO and Gavi co-sponsored ACT Accelerator initiative, which aims to hasten the distribution of Covid-19 vaccines, drugs and tests across the world, they fall short of clearly committing desperately needed new funding to it. 

A weak G-20 commitment would be a blow to the WHO-backed scheme, Flauhault said, adding that if there was sufficient political will, the US and its allies could potentially vaccinate the whole planet.

“It would cost about 27 billions of dollars to immunize the world population, which is affordable. A country like the US, which I am not saying should vaccinate the world, could however do so if it wanted to. If not high income countries should invest in doing so as soon as possible,” Flahault said.  

At the same time, this year’s WHA will see solid support from the United States, following the change in the administration – and Washington is expected to be a big player in the proceedings. 

Read also: Fauci signals new chapter in US relations with the WHO

“The US body-language is quite important because they have recently been a big defender for multilateralism,” said Liu.

“These are good signals for global health and particularly during the pandemic.  They are pushing back on the waivers of patents, and should also really consider funding the Covax equitable vaccine sharing scheme,”  Flahault added. 

COVID Will Become a Pandemic of the Poor if Neglected Now

The pandemic may become a disease of the poor if nothing is done; coronavirus lockdown in a Roma community in Romania. Makeshift barracks leaves it difficult to follow social distancing and basic hygiene rules.

In the absence of strong action by wealthy donor countries at the G-20 and the WHA, the trajectory of COVID risks the disease becoming a “pandemic of the poor”, Liu warns.

For Liu, if the opportunity is not seized at this year’s WHA to adequately address the WHA, by taking bold decisions and committing to actions then she believes COVID will become an endemic disease, mostly but will be limited to low and middle income countries, whilst high income countries leave the rest of the world behind.  

 “My biggest worry is that high income countries will pull themselves out of the grip of COVID-19 because they will vaccinate the population, and have herd immunity. Low and middle income countries will then be stuck, just like what happened with  HIV and Tuberculosis,” she said. 

The Question of Taiwan

Former Taiwan Vice President Chen Chien-jen in an interview in 2017 discussing the absence of an invitation for Taiwan to attend the World Health Assembly.

In 2008, Taiwan was invited every year to the WHA as an “observer” but since 2016, this invitation – issued at the discretion of the WHO Director General – ceased. This was after Taiwanese elections brought a new government into power with a more hard-line stance toward China – leading Beijing to oppose the seat for Taiwan in the Assembly – even as an observer.  

In the wake of the pandemic, which saw allegations of a Chinese cover-up of the SARS-CoV2 virus origins, as well as a refusal then and now to share critical data around the outbreak’s early days,  there have  been growing  calls to renew the invitation to Taipei – beginning already last year.  

For this year’s 74th WHA, some 13 WHO member states have called for Taiwan to be allowed to participate, with the issue set to be discussed on Monday.  This includes the G-7 (Group of Seven most industrialized countries), which have formally  endorsed Taiwan’s attendance. 

The participation of Taiwan is critical for scientific reasons,  says Flahault. “In global health and security terms, there is absolutely no doubt that Taiwan should be one of the full members of the WHA. The way the country has managed the pandemic offers great tools and lessons which will be important knowledge to share at the WHA and it is a pity if we do not get this,” he said. 

From Taiwan to vaccine equity, the challenge throughout all of the WHA debates will be for individual member states to rise above their own narrow set of national or geopolitical interests – recognising that the pandemic is a threat to all.  

“What I expect from the WHA is that member states show exemplary leadership. This year has to be a game changer in terms of response and preparedness to pandemic,” said Liu.

Republished from Geneva Solutions. Health Policy Watch Watch is collaborating with Geneva Solutions, a new non-profit Geneva platform for constructive journalism covering International Geneva

Image Credits: WHO / Antoine Tardy, Antoine Flahault, IPPR, UNGA, Tadeau Andre/MSF , Thomas Hackl/Flickr, Flickr – Taiwan Presidential Office.

ip
A network analysis of COVID-19 mRNA vaccine patents

Governments and pharmaceutical companies alike must work together in combating the ‘virus of intellectual property (IP) monopolies over COVID-19 vaccines – which  further exacerbates inequality and lack of access to vaccines for vulnerable groups. 

That was the uptake of a group of experts speaking at a webinar Wednesday on “The Virus of IP Monopoly Capitalism”’ hosted by the Society for International Development (SID)

“What we need is collective intelligence, not the segmentation of different actors, allowing each person possible to participate in the production process,” said Ugo Pagano of the Italy-based Siena University, during a webinar 

The symposium discussed current global tensions between proponents of the proposed World Trade Organization (WTO) TRIPS waiver to accelerate access to COVID-19 vaccines – and its pharma industry opponents who support a system that they say stimulates innovation – even if the benefits may be unevenly distributed.  

Intangibles Controlling Global Economy

The smiling curve of intangibles – Investor state dispute settlements shift power to private actors and increases value of intangibles

IP, or ‘intangibles’, are “‘considered a lion’s share of powers concentrated in the global economy”, said Susan Sell of the Australian National University.

Intangibles are IP trademarks and patents that play an outsized role in the global economy, with the political and economic powers that own those goods controlling the value of oft-essential products and services. 

In terms of the COVID-19 pandemic, that can include patents governing tests, Personal Protective Equipment (PPE), vaccines, and medicines. 

“It’s a winner-takes-most system right now – and those who own the intangibles are the winners in this system,” said Sell. 

This means that developed countries and pharmaceutical companies are the “winners” of this system, said Sell, with developing countries and vulnerable groups struggling to access essential equipment and treatment, worsening inequality and poverty, and leading to many unnecessary COVID deaths. 

IP Regulation is Not Sustainable 

IP

Experts argued that protecting IP so as to stimulate innovation is not a sustainable model. The COVID crisis has forced the world to rethink issues around the efficiency and efficacy of IP regulation moving forward.

“[It is now the time] to start raising some questions about the sustainability of [IP regulations],” said Mohammed El Said, of the University of Central Lancashire, United Kingdom.

“The COVID-19 pandemic is not the first pandemic and it won’t be the last. However, our ability in dealing with and actually having the correct and right mechanisms in limiting its impact will, [in turn] impact how we’re actually going to deal with future occurrences of this nature.” 

Although more and more of the world’s population are now able to access COVID vaccines, which El Said called a ‘turning point in the fight against the pandemic’, sufficient supplies have yet to reach developing countries. 

Vaccine nationalism is ‘counterproductive’ to the vaccine supply problem, because while most developed countries have access to vaccines, the pandemic will still persist in other countries and regions that are now labeled hotspots, such as India and Latin America and the Caribbean, prompting all the hard work in fighting the vaccine to be undone. 

Future of Global Economy – Innovation Towards Delivering Global Public Goods 

Susan Sell, School of Regulation and Global Governance, Australian National University

The future of the global health economy must shift towards a model where innovation, which is now left to the markets, would instead be the basis for a model that can deliver global public goods.  

There’s a ‘reduced commitment to social policy in the face of imperatives of finance capitalism’, said Sell.  “It’s really about profits, it’s really about shareholder value.”

This, according to her, causes economic powers to block social and reform initiatives if they have the potential to threaten either profits or shareholder value. 

Evidence of this can be seen in the resistance by countries with large pharma interests, such as Germany, to waiving patent protections. German officials believe that the United States’ support of the TRIPS waiver would create ‘severe complications’ for the production of vaccines, a German government spokeswoman told Bloomberg recently. 

The spokeswoman argued that the limiting factor for the production of vaccines is manufacturing capacities and high quality standards, not the patents, countering the point made by experts during the webinar to shift  market innovation towards increased accessibility of global public goods.

Monopoly on Knowledge Impacts Vaccine Production and Supply

Els Torreele, Institute for Innovation and Public Purpose; University College London

However, Els Torreele of the University College London asserted at the webinar that the protection of IP through monopolies, also impacts production capabilities and technologies, leading to vaccine hoarding and the buying up of available stock. 

“[These monopolies] have led us to the situation that we’re in,” said Torreele, noting that the public ends up on the ‘losing end’ of this situation. 

“We’re confronted with this highly unequal and inequitable situation”, she added.

As a way forward, Torreele cited the recommendations contained in the recent report of The Independent Panel to transform the Access to COVID-19 Tools Accelerator (ACT-Accelerator) into a truly global end-to-end platform for development and rollout of vaccines, diagnostics, therapeutics, and essential supplies. 

“We need to make sure all our efforts result in equitable access.” 

Image Credits: Nature Biotechnology, OECD, Open Source/Flickr.

Malawi Health Minister Khumbize Chipondo places a bag of COVID-19 vaccines in an incinerator in Lilongwe. The country burned nearly 20 000 expired AstraZeneca vaccines on Wednesday.

Malawi on Wednesday burned nearly 20,000 doses of expired AstraZeneca COVID-19 vaccines. The government move happened shortly after the Serum Institute of India (SII) announced that it would only resume its export of the precious vaccines to the rest of the world at the end of 2021 – due to the still burning pandemic crisis on the Indian subcontinent. 

Malawian health authorities said that they had incinerated 19, 610 doses of the vaccines, produced by the SII, at the Kamuza Central Hospital in the capital Lilongwe – which the country had been unable to administer prior to expiration.

The vaccines were the remainder of a batch of 102, 000 doses that arrived in Malawi on 26 March – with some doses marked with an expiration date that was just 18 days later, or 13 April, said health secretary Charles Mwansambo in a statement.

Decision Goes Against Pleas by WHO and Africa CDC to Use the Vaccines

The decision to destroy the vaccines goes against early pleas by the Africa CDC and the World Health Organization. Last month the two organisations urged African countries not to destroy COVID-19 vaccines that had passed their expiration dates, saying they were still safe to use.

Africa CDC director, John Nkengasong, citing the example of the Democratic Republic of Congo, said that instead of destroying vaccines, countries should redistribute vaccines that they cannot use to other Member States.

“During a time where access to COVID-19 vaccines is particularly difficult for Africa, utilising an entire vaccine consignment could have been accomplished without much challenge,” said director Africa CDC, John Nkengasong said on 6 May during a weekly briefing.

If, for example, governments set a goal of administering a minimum of 5, 000 vaccine doses per day for just 10 days, an entire consignment of vaccines would be fully utilised well before the listed manufacturer expiration date, said Nkengasong.

Malawi’s destruction of the vaccine should be a lesson to other countries to better plan their vaccination programmes, said Professor Pontiano Kaleebu of the Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine

“What happened in Malawi is a learning experience and should be used to encourage people to get vaccinated so that the vaccines do not expire elsewhere. Many people in Africa have not come to get the vaccine, which is not what we expected. It is a big problem that needs to be addressed,” Kaleebu added.  

Said Nkengasong: “Given the urgent need to save as many lives as possible, countries were informed by the Africa CDC to vaccinate quickly. It is indeed, critical to use such donations in a timely fashion in order to save lives and bring the pandemic to an end on the continent”.

Message To Not Destroy Came Too Late

The Malawian government however contends that the communication from the WHO and Africa CDC came too late.

Health Ministry spokesperson Joshua Malango telling Health Policy Watch that by the time they received communication they had already removed the vaccines from the cold storage systems and it was deemed unfit for use. 

“By the 14th of April we had already removed the unused COVID-19 vaccines from the refrigerators,” said Malango, adding that the communication from WHO came in after Malawi had sought clarity from the SII, from which the vaccines were procured. The SII, said Malango, had formally responded , indicating an approved “shelf-life extension” for an additional three months, through 13 July 2021.

Out of a population of about 18 million people, the country has recorded 34,232 confirmed coronavirus cases and 1,153 deaths. To date,  the country has vaccinated 330,336 people.

The country received  360,000 AstraZeneca doses from the COVAX facility in March and received another batch of 50,000 of the same dose from the Indian government.  The expired doses were part of a donation from the African Union. 

At a media briefing, Mwansambo assured Malawians that “we still have adequate stocks of COVID-19 vaccines”, and that a second dose of AstraZeneca would be administered  to high-risk groups that had received their first dose, beginning on 3 June. Mwansambo also told reporters that health officials had been concerned that using expired vaccines could scare off people from getting vaccinated.

WHO and partners released guidance on COVID-19 vaccination planning and deployment for national governments, with the aim to help them design strategies for the deployment, implementation, and monitoring of COVID-19 vaccines and better integrate their strategies and financing to boost efficiency.

The global health body advised countries that prior to receiving the vaccines they should thoroughly prepare and ensure the logistics including cold chain maintenance, training of health workers, a system to manage the demands of injections devices-syringes and needles, and to follow adverse events. Countries also have to pre-register and create databases for vaccine uptake.

Exports of AstraZeneca from SII by End of 2021

Meanwhile, in a statement on Tuesday, Serum Institute of India chief Adar Poonawalla said that SII is scaling up its manufacture of vaccines, but would be prioritising India for the remainder of 2021.

“We also hope to start delivering to COVAX and other countries by the end of this year,” he said in the statement.

Poonawalla said there has been intense discussion between SII, the Indian government and other vaccine manufacturers in the past few days on the export of vaccines.

Although SII had commitments to the COVAX facility, he said that the domestic needs still take precedence and the vaccination drive in India “cannot be completed within two to three months, as there are several factors and challenges involved”.

 

Image Credits: Joshua Malango.